ZA200607159B - Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases - Google Patents

Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases

Info

Publication number
ZA200607159B
ZA200607159B ZA200607159A ZA200607159A ZA200607159B ZA 200607159 B ZA200607159 B ZA 200607159B ZA 200607159 A ZA200607159 A ZA 200607159A ZA 200607159 A ZA200607159 A ZA 200607159A ZA 200607159 B ZA200607159 B ZA 200607159B
Authority
ZA
South Africa
Prior art keywords
antagonists
receptor
manufacture
treatment
composition useful
Prior art date
Application number
ZA200607159A
Other languages
English (en)
Inventor
Lotersztajn Sophie
Mallat Ariane
Grenard Pascale
Julien Boris
Tran Van Nhieu Jeanne
Original Assignee
Inst Nat Sante Rech Med
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Sanofi Aventis filed Critical Inst Nat Sante Rech Med
Publication of ZA200607159B publication Critical patent/ZA200607159B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA200607159A 2004-03-09 2006-08-28 Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases ZA200607159B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04290633A EP1574211A1 (en) 2004-03-09 2004-03-09 Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases

Publications (1)

Publication Number Publication Date
ZA200607159B true ZA200607159B (en) 2008-02-27

Family

ID=34814417

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200607159A ZA200607159B (en) 2004-03-09 2006-08-28 Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases

Country Status (27)

Country Link
US (2) US8236763B2 (ru)
EP (3) EP1574211A1 (ru)
JP (1) JP2007527893A (ru)
KR (1) KR20070026415A (ru)
CN (1) CN1929828A (ru)
AR (1) AR048087A1 (ru)
AT (1) ATE520393T1 (ru)
AU (1) AU2005218937B2 (ru)
BR (1) BRPI0508560A (ru)
CA (1) CA2557976A1 (ru)
CY (1) CY1112078T1 (ru)
DK (1) DK1725223T3 (ru)
ES (1) ES2371552T3 (ru)
HK (1) HK1094674A1 (ru)
IL (1) IL177465A0 (ru)
MA (1) MA28454B1 (ru)
MX (1) MXPA06010287A (ru)
NO (1) NO20064603L (ru)
PL (1) PL1725223T3 (ru)
PT (1) PT1725223E (ru)
RU (1) RU2402328C2 (ru)
SI (1) SI1725223T1 (ru)
TN (1) TNSN06272A1 (ru)
TW (1) TWI337540B (ru)
UA (1) UA94025C2 (ru)
WO (1) WO2005084652A2 (ru)
ZA (1) ZA200607159B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
US7875647B2 (en) 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
BR112013000841A2 (pt) * 2010-07-15 2016-06-07 Oleg Lliich Epshtein composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano.
US20120288442A1 (en) * 2011-05-11 2012-11-15 Atomic Energy Council-Institute Of Nuclear Energy Research Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis
US11155521B2 (en) 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
CA2889697C (en) 2012-11-13 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
MX2016012403A (es) 2014-03-27 2017-06-14 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano.
JP6762930B2 (ja) 2014-05-09 2020-09-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ カンナビノイド受容体メディエータとしてのピラゾール誘導体およびそれらの使用
CA3000167A1 (en) 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
WO2017184412A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100293A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
AT394493B (de) * 1989-05-11 1992-04-10 Homosan Ag Pharmazeutisches praeparat zur behandlung von lebererkrankungen
US5492891A (en) * 1991-09-05 1996-02-20 Novo Nordisk A/S Method for treatment of patients with chronic liver disease
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US6143752A (en) * 1997-08-01 2000-11-07 Oren; Ran Method for preventing or arresting liver damage in humans
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2809621B1 (fr) 2000-05-12 2002-09-06 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
US6465436B2 (en) * 2000-06-01 2002-10-15 Mclean Hospital Method for treating alcohol intoxication and alcohol abuse
LU90996B1 (en) * 2000-07-11 2003-01-08 Bayer Ag Use of the strains of the parapox ovis virus against fibrosis
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
FR2837706A1 (fr) 2002-03-28 2003-10-03 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
JP2005527586A (ja) * 2002-04-05 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド 置換アリールアミド
FR2838438A1 (fr) * 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2838439B1 (fr) * 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
AU2003223510B2 (en) 2002-04-12 2008-05-08 Merck Sharp & Dohme Corp. Bicyclic amides
US20040034968A1 (en) * 2002-06-14 2004-02-26 Hufcor, Inc. 360 Degree hinge and door closure apparatus
SE0202242D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Compounds
SE0202240D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Genes
JP4667867B2 (ja) * 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
FR2849032B1 (fr) * 2002-12-23 2006-04-28 Sanofi Synthelabo Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
WO2005020992A1 (en) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Novel medical use of selective cb1-receptor antagonists
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
FR2861303A1 (fr) 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
RU2006117637A (ru) * 2003-10-24 2007-12-10 Зольвай Фармасьютиклз Гмбх (De) Комбинированное лечение ожирения с применением избирательных антагонистов cb1-рецептора и ингибиторов липаз
GB0403780D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
EP1574211A1 (en) 2005-09-14
EP2305220A3 (en) 2011-05-18
TWI337540B (en) 2011-02-21
HK1094674A1 (en) 2007-05-18
EP1725223B1 (en) 2011-08-17
WO2005084652A2 (en) 2005-09-15
RU2402328C2 (ru) 2010-10-27
UA94025C2 (ru) 2011-04-11
ES2371552T3 (es) 2012-01-05
US20080214449A1 (en) 2008-09-04
KR20070026415A (ko) 2007-03-08
ATE520393T1 (de) 2011-09-15
EP2305220B1 (en) 2014-07-30
TNSN06272A1 (en) 2007-12-03
CN1929828A (zh) 2007-03-14
US8236763B2 (en) 2012-08-07
BRPI0508560A (pt) 2007-08-14
EP1725223A2 (en) 2006-11-29
NO20064603L (no) 2006-10-09
PL1725223T3 (pl) 2012-01-31
AU2005218937B2 (en) 2011-07-07
RU2006134707A (ru) 2008-04-20
PT1725223E (pt) 2011-12-02
IL177465A0 (en) 2007-07-04
US20120329833A1 (en) 2012-12-27
CY1112078T1 (el) 2015-11-04
EP2305220A2 (en) 2011-04-06
AU2005218937A1 (en) 2005-09-15
US8604060B2 (en) 2013-12-10
AR048087A1 (es) 2006-03-29
MXPA06010287A (es) 2007-02-14
JP2007527893A (ja) 2007-10-04
DK1725223T3 (da) 2011-11-28
TW200534851A (en) 2005-11-01
SI1725223T1 (sl) 2012-01-31
WO2005084652A3 (en) 2005-12-08
MA28454B1 (fr) 2007-03-01
CA2557976A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
HK1094674A1 (en) Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases cb1
ZA200608955B (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
ZA200707498B (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
IL179462A0 (en) Use of the receptor gpr86
IL245387A0 (en) A new use for il–1 beta compounds
GB0524428D0 (en) Medicinal use of receptor ligands
EP1817545A4 (en) INTERFEROMETRICAL ANALYSIS FOR MANUFACTURING DEVICES IN NANOGROSIS
GB0404124D0 (en) Antagonists of GIP
EP1814550A4 (en) ANTAGONISTS OF N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1
IL183255A0 (en) New process for the preparation of a leukotriene antagonist
IL190686A0 (en) Il-21 receptor antagonists
IL204407A0 (en) 3' substituted compounds having 5 - ht6 receptor affinity
SI1863476T1 (sl) Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
ZA200710611B (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
GB0416728D0 (en) Medicinal use of receptor ligands
EP1899318A4 (en) NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
IL201974A0 (en) 4' substituted compounds having 5-ht6 receptor affinity
PT1833821E (pt) Sulfamidas como antagonistas do receptor de endotelina para o tratamento de doenças cardiovasculares
WO2007115975A3 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
HU0500145D0 (en) Composition for the treatment of oral diseases
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
EP1732599A4 (en) USE OF EMMPRINE ANTAGONISTS FOR THE TREATMENT OF DISEASES RELATED TO EXCESSIVE ANGIOGENESIS
EP1819346A4 (en) OXYTOCIN RECEPTOR ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF LUNG DISEASES
GB0414196D0 (en) Medicinal use of receptor ligands